Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss

New data shows significant loss of fat mass while maintaining lean mass

NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, Inc. today announced… (NYSE: ALUR), a company dedicated to eliminating obesity, announced three scientific presentations at the 31st European Congress on Obesity (ECO) in Venice, Italy. , on May 12-15, 2024.

The presentations include data from a study of 712 patients treated with the Allurion program, which is based on the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion's proprietary behavior change software. This study was conducted in six obesity centers in six countries, and the data showed that patients achieved a total body weight loss (TBWL) of 14.1% on average over 4 months, 70% of which came from fat mass and only 30% of which came from lean body mass. .

The Allurion Program is designed to monitor both weight loss and lean body mass, facilitate fundamental changes in behavior that can protect skeletal muscle, and reduce the impact on lean body mass during periods of rapid weight loss, said Dr. Shantanu Gaur, Founder and CEO of Allurion. From Alorion. Research shows that maintaining lean body mass while losing weight is critical to maintaining metabolic health and achieving positive, sustainable results.

Current obesity interventions—including anti-obesity medications such as GLP-1s and bariatric surgery—are often not delivered through training or behavior change programs designed to protect lean body mass, which can lead to a significant reduction in muscle mass. For example, GLP-1 has been shown to result in approximately 40% loss of lean body mass within one year of treatment.

Maintaining lean body mass in the presence of a large calorie deficit is challenging. “We believe Allurion makes this possible through body composition monitoring and a personalized program that focuses on results beyond just weight,” said Dr. Ram Chotani, Allurion's chief medical officer. We will continue to partner with Allurion providers to help them improve outcomes for their patients through training, support and our digital health platform.

With more intense programs, early data suggests that loss of muscle mass can be avoided altogether. In a previous study similar, but smaller in size, to the highly intensive multidisciplinary Allurion program with weekly follow-up, patients achieved 14.6% TBWL at 4 months, and actually increased lean body mass, with 100% of weight loss derived from fat mass. 3

These results suggest that the Allurion program may be more protective of muscle mass during weight loss than alternative methods, Gower continued. I look forward to exploring how we can leverage the Allurion Virtual Care Suite and Coach Iris to provide a more personalized and intense training program for our patients and potentially eliminate muscle mass loss altogether without significant human intervention.

The ECO presentations also include statements about the positive impact of the behavior change training skills course developed by Allurion and the positive impact of GLP-1s on the Allurion program.

Details of the offers are as follows:

Body Composition Changes During the Non-Swallowable, Non-Endoscopic Gastric Balloon Program (SIGBP): Prioritizing Preservation of Lean Mass for Sustainable, Healthy Weight Loss
Presenter: Roberta Enka, MD, Weight Management Center, Nova Villa Claudia Clinic

Training health care professionals in behavior change coaching skills improves weight loss outcomes for the swallowable, non-endoscopic gastric balloon program.
Presenter: Zoe Griffiths, B.Sc. RD, Senior Director of Behavioral Medicine, Allurion

Halo effect of anti-obesity medications: Increased interest in medications is leading to increased awareness and uptake of other medical obesity treatments
Presenter: Zoe Griffiths, B.Sc. RD, Senior Director of Behavioral Medicine, Allurion

For more information about ECO 2024, please visit: https://eco2024.org/.

Sources: 1. Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002. 2. McCrimmon RJ, Catarrig AM, Frias JP, et al. diabetes. 2020;63(3):473-485. 3. Raftopoulos and Giannakou. Surg L Obes and Rel Dis. 2017;13:1174-1182.

About Alorion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world's first and only swallowable, non-procedure intragastric balloon for weight loss, and provides access to the Allurion Virtual Care Suite, including the Allurion mobile app for consumers, Allurion Insights for healthcare providers featuring the Coach Iris AI platform and Allurion Connected scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion software to help customize, monitor and manage weight loss treatment for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion gastric balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care range, please visit the website www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. In the United States and countries around the world.

Forward-looking statements

This press release may contain certain forward-looking statements within the meaning of U.S. federal and state securities laws. These forward-looking statements are generally identified by the words “believe, project, expect, expect, estimate, intend, strategy, future, opportunity, plan, may, should, will, will, will continue, likely to result, and” Similar expressions include statements regarding the ability of the Allurion program, including VCS, to improve patient outcomes and clinical outcomes, including outcome improvements over time, the effect of the behavior change coaching skills course, and the effect of gLP-1s on the Allurion program. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion's management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements contained in this communication, including but not limited to (1) Allurion's ability to obtain and maintain regulatory approvals for the Allurion program and successfully commercialize it, including That is, the Allurion Balloon and VCS, (2) the timing and results of our studies and clinical trials, (3) the development of the markets in which Allurion competes, (4) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the war between Russia and Ukraine, and the conflict between Israel and Hamas over Allurion's business, (vi) Allurion's expectations regarding its market opportunities, including those for the VCS platform, and (vii) risks from economic downturns and the changing regulatory landscape in the highly competitive industry in which Allurion operates. The above list of factors is not exhaustive. You should carefully consider the above factors and the other risks and uncertainties described in the Risk Factors section of Allurion's Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the SEC. . These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Allurion undertakes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Allurion makes no guarantees that it will meet its expectations.

View source version on Businesswire.com: https://www.businesswire.com/news/home/20240515859813/en/

Global media:
Cédric D'Amour
public relations manager
+33 7 84 21 02 20
cdamour@allurion.com

Investors:
Mike Cavanaugh, Investor Relations
ICR Westwick
(617) 877-9641
mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.